Novo Nordisk

Largest shareholder in action

19/05/25 -"Novo’s decision to oust its CEO came as a surprise, as the largest shareholder, the Novo Nordisk Foundation, decided to take action to prevent further shareholder wealth erosion, which has been ..."

PDF page sample
Pages
73
Language
English
Published on
19/05/25
Download
You may also be interested by these reports :
20/05/25
With 2025 having started on a strong note – on the back of a healthy performance across the segments – we have upgraded our earnings estimates for ...
19/05/25
Novo’s decision to oust its CEO came as a surprise, as the largest shareholder, the Novo Nordisk Foundation, decided to take action to prevent ...
19/05/25
Merck’s business model should not be that much impacted by the current global uncertainty but the depreciation of the USD has triggered, among other ...
15/05/25
Merck’s decision to provide detailed FY guidance was overshadowed by the significant impact of US President Trump’s actions. Consequently, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO